Skip to content
No results
  • Home
  • News
  • Press Releases
  • Business
  • Technology
  • Research
  • Regulatory
  • Events and Conferences
  • About Us
  • Contact Us
  • About Us
  • Contact Us
The Pharma Data
  • News
  • Press Releases
  • Business
  • Technology
  • Research
  • Regulatory
  • Events and Conferences
The Pharma Data
  • Research

Automated Liquid Handling Systems Market 2024-2029: AI, Lab Complexity, & Miniaturization Trends

  • The Pharma Data
  • June 8, 2024

The “Global Automated Liquid Handling Systems Market – Outlook & Forecast 2024-2029” report is now available from ResearchAndMarkets.com. The market is projected to grow from $1.46 billion in 2023 to…

Read MoreAutomated Liquid Handling Systems Market 2024-2029: AI, Lab Complexity, & Miniaturization Trends
  • Press Releases

UroGen Pharma Announces Inducement Grants in Accordance with Nasdaq Listing Rule 5635(c)(4)

  • The Pharma Data
  • June 8, 2024

UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company focused on developing and commercializing innovative treatments for urothelial and specialty cancers, today announced the granting of inducement restricted stock units (RSUs)…

Read MoreUroGen Pharma Announces Inducement Grants in Accordance with Nasdaq Listing Rule 5635(c)(4)
  • Regulatory

BWXT Medical Submits Actinium-225 API Drug Master File to FDA

  • The Pharma Data
  • June 8, 2024

BWXT Medical Ltd. has submitted a Drug Master File (DMF) to the U.S. Food and Drug Administration (FDA) for No Carrier Added (n.c.a.) Actinium-225 (Ac-225) Active Pharmaceutical Ingredient. Ac-225 is…

Read MoreBWXT Medical Submits Actinium-225 API Drug Master File to FDA
  • Press Releases

Vertex Showcases TRIKAFTA® Benefits at European Cystic Fibrosis Conference

  • The Pharma Data
  • June 8, 2024

Today, Vertex Pharmaceuticals announced the presentation of new data on TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor), known in the European Union and the U.K. as KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in combination with ivacaftor, at…

Read MoreVertex Showcases TRIKAFTA® Benefits at European Cystic Fibrosis Conference
  • Press Releases

Lilly’s Chief Financial Officer, Anat Ashkenazi, to Step Down

  • The Pharma Data
  • June 6, 2024

Today, Lilly announced that Anat Ashkenazi, the company’s Chief Financial Officer (CFO), has resigned from her position to pursue a career opportunity outside the pharmaceutical industry. David A. Ricks, the…

Read MoreLilly’s Chief Financial Officer, Anat Ashkenazi, to Step Down
  • News

Being Diagnosed with Lung Cancer Was the Last Thing I Expected

  • The Pharma Data
  • June 6, 2024

Deborah Borst, a 74-year-old resident of Michigan, never fretted over her health, enjoying a life marked by robust well-being. Her hospital visits were limited to the joyous occasions of childbirth.…

Read MoreBeing Diagnosed with Lung Cancer Was the Last Thing I Expected
  • Regulatory

Top 4 Insights from Johnson & Johnson’s 2023 Health for Humanity Report

  • The Pharma Data
  • June 6, 2024

Since its founding in 1886, Johnson & Johnson has been dedicated to addressing major health challenges and promoting a healthier world. Today, the company released its 2023 Health for Humanity…

Read MoreTop 4 Insights from Johnson & Johnson’s 2023 Health for Humanity Report
  • Business

Invite Friends to Join Allē, Allergan Aesthetics’ Loyalty Program, and Earn $50

  • The Pharma Data
  • June 6, 2024

Today marks the launch of “Refer a Friend,” a new feature from Allē, Allergan Aesthetics’ Loyalty Rewards Program. Allē members can now invite friends and family to join, allowing both…

Read MoreInvite Friends to Join Allē, Allergan Aesthetics’ Loyalty Program, and Earn $50
  • Business

RINVOQ® Approved for Kids 2+ with JIA and Psoriatic Arthritis

  • The Pharma Data
  • June 6, 2024

AbbVie announced that RINVOQ® (upadacitinib) is now approved in the U.S. for treating pediatric patients aged two years and older with active polyarticular juvenile idiopathic arthritis (pJIA) and psoriatic arthritis…

Read MoreRINVOQ® Approved for Kids 2+ with JIA and Psoriatic Arthritis
  • Press Releases

AbbVie Launches Phase 3 Trial for Multiple Myeloma Drug ABBV-383

  • The Pharma Data
  • June 6, 2024

Today, AbbVie announced the first patient has been treated with ABBV-383 in the CERVINO Phase 3 study. ABBV-383 is a bispecific antibody T-cell engager targeting BCMA and CD3, featuring high…

Read MoreAbbVie Launches Phase 3 Trial for Multiple Myeloma Drug ABBV-383
  • News

Incyte Completes Acquisition Of Escient Pharmaceuticals

  • The Pharma Data
  • June 1, 2024

Incyte has finalized its acquisition of Escient Pharmaceuticals, a company specializing in the development of small molecule therapeutics for immune and neuro-immune disorders. The acquisition enhances Incyte’s Inflammation and Autoimmunity…

Read MoreIncyte Completes Acquisition Of Escient Pharmaceuticals
  • News

WuXi Biologics Unveils 2023 ESG Report Showcasing Robust Sustainability Initiatives

  • The Pharma Data
  • June 1, 2024

WuXi Biologics, a prominent global Contract Research, Development, and Manufacturing Organization (CRDMO), has released its 2023 Environmental, Social, and Governance (ESG) Report, showcasing significant advancements in sustainable development. Aligned with…

Read MoreWuXi Biologics Unveils 2023 ESG Report Showcasing Robust Sustainability Initiatives
PrevNext

About

The Pharma Data is an Information-Centric Website focused mainly on the Pharmaceutical Industry Online It is a B2B Platform mainly focused on the latest Pharmaceutical News, Press releases, Industry-related updates, Events, and Conferences. With The Pharma Data, you can get all the information that happening in the Pharmaceutical industry.

Advertise With Us: marketing@thepharmadata.com

Latest Posts

  • EmeraNova™ Strengthens Innovation Leadership with Launch of New Accelerator ProgramNovember 5, 2026
  • Global Healthy Living Foundation Highlights Advances in Myositis and Polymyalgia Rheumatica Research at ACR Convergence 2026November 5, 2026
  • Polaris Rx Chosen by Bristol Myers Squibb to Distribute ZENBEXUS™, the First FDA-Approved CELMoD Treatment for Multiple MyelomaNovember 5, 2026
  • About Us
  • Disclaimer
  • Privacy Policy
  • Terms and Conditions
  • Contact Us

Copyright © 2026 | The Pharma Data | Marnet Technologies Pvt Ltd | All Rights Reserved.